Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: Evidence for interactive effects of flavopiridol, LY 294002, roscovitine, wortmannin and UCN-01

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 101-106

  Cory, Ann H ^a   Somerville, Lilla ^a   Cory, Joseph G ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Apoptosis; Cyclin cdk's; Deoxyadenosine resistance; Flavopiridol; Leukemia cells; LY294002; p53; Phosphoinositol 3 kinase; PKC; Roscovitine; UCN 01; Wortmannin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEOXYADENOSINE; DEOXYADENOSINE TRIPHOSPHATE; FLAVOPIRIDOL; HYDROXYUREA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN C FOS; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; ROSCOVITINE; THIOSEMICARBAZONE; WORTMANNIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; LEUKEMIA CELL; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CASPASES; CHROMONES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FLAVONOIDS; LEUKEMIA L1210; MICE; MORPHOLINES; PIPERIDINES; PROTEIN KINASE C; PURINES; STAUROSPORINE;

EID: 16344395659     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cory JG, Fleischer AE and Munro JB, III: Reconstitution of the ribonucleotide reductase from Ehrlich tumor cells. J Biol Chem 253: 2898-2901, 1998.
2. Cory JG and Fleischer AE: Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy. Cancer Res 39: 4600-4604, 1979.
3. Sato A, Carter GL, Bacon PE and Cory JG: Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on the growth of L1210 cells. Cancer Res 42: 4353-4357, 1982.
4. Thelander L and Berg P: Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol 6: 3433-3442, 1986.
5. Carter GL and Cory JG: Cross resistance patterns in hydroxyurea-resistant leukemia L1210 cells. Cancer Res 48: 5796-5799, 1988.
6. Cory JG and Carter GL: Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors. Cancer Res 48: 5796-5799, 1988.
7. Carter GL and Cory JG: Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase. Advan Enzyme Regul 29: 123-139, 1989.
8. Cory AH, Sato A, Thompson DP and Cory JG: Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formyl-isoquinoline thiosemicarbazone. Oncology Res 8: 449-456, 1996.
9. Rappa G, Lorico A, Lui M-C, Kruh GD, Cory Ah, Cory JG and Sartorelli AC: Overexpression of the multidrug resistance genes mdr1 , mdr3 and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 54: 649-655, 1997.
10. Cory JG, Cory AH, Lorico A, Rappa G and Sartorelli AC: Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formyl- isoquinoline thiosemicarbazone. Anticancer Res 17: 3185-3194, 1997.
11. Crenshaw TR and Cory JG: Overexpression of protein disulfide isomerase-like protein in a mouse leukemia L1210 cell line selected for resistance to 4-methyl-5-amino-1-formyl-isoquinoline thiosemicarbazone. Advan Enzyme Regul 42: 143-157, 2002.
12. Cory JG, Cory AH, Long SD, Carter GL and Johnson CE: Altered steady-state levels of the messenger RNAs for c-myc and p53 in L1210 cell lines resistant to deoxyadenosine. Cancer Res 52: 2000-2003, 1992.
13. Cory JG, He A-W and Cory AH: Deoxyadenosine-resistant mouse leukemia L1210 cell lines with alterations in early response genes and p53. Anticancer Res 16: 3483-3490, 1996.
14. He A-W and Cory JG: Effect of ionizing radiation on wild-type and mutant mouse leukemia L1210 cells. Oncology Res 10: 455-464, 1998.
15. He A-W and Cory JG: p53-independent anisomycin induced G1 arrest and apoptosis in L1210 cells. Anticancer Res 19: 421-428, 1999.
16. Somerville L and Cory JG: Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors. Anticancer Res 19: 1021-1026, 1999.
17. He A-W and Cory JG: Effect of doxorubicin on wild-type and deoxyadenosine-resistant mouse leukemia L210 cells. Int J Oncology 14L: 891-895, 1999.
18. Somerville L and Cory JG: Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to apoptosis induced by 7-hydroxystaurosporine. Int J Oncology 17: 797-803, 2000.
19. Somerville L and Cory JG: Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Anticancer Res 20: 3347-3356, 2000.
20. Cory AH, Hickerson DHM and Cory JG: Apoptosis induced by inhibitors of nucleotide synthesis in deoxyadenosine-resistant leukemia L1210 cells that lack p53 expression. Anticancer Res 20: 4171-4178, 2000.
21. Hall JG, Hickerson DHM and Cory JG: Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells. Anticancer Res 21: 173-180, 2001.
22. Cory AH and Cory JG: Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NFkappa B activation. Anticancer Res 21: 3807-3812, 2001.
23. Cory AH and Cory JG: Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappa B activation on drug-resistant mouse leukemia 11210 cells. Anticancer Res 22: 3805-3810, 2002.
24. Cory AH and Cory JG: Gemicitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53. Advan Enzyme Regul 44: 11-25, 2004.
25. Krishan A: Rapid flow cytometry analysis of mammalian cell cycle by propodium iodide staining. J Cell Biol 66: 188-193, 1975.
26. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E and Grever MR: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92: 3804-3816, 1998.
27. Parker BW, Kaur G, Nieves-Neira W, Tiami M, Kohlhagen G, Shimizu T, Losienwicz MD, Pommier Y, Sausville EA and Senderowicz AM: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91: 458-465, 1998.
28. Vlahos CJ, Malter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinosotol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248, 1994.
29. Cross MJ, Stewart A, Hodgkin MN, Kerr DJ and Wakelam MJ: Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swill 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem 270: 25352-25355, 1995.
30. Downing GJ, Kim S, Nakanishi S, Catt KJ and Balla T: Characterization of a soluble adrenal phosphoinositol 4-kinase reveals Wortmannin sensitivity of type III phosphoinositol kinases. Biochemistry 35: 3587-3594, 1996.
31. Rosenzweig KE, Youmell MB, Palayoor ST and Price BD: Radiosentization of human cells by phosphatidylinositol 3-kinase inhibitors Wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3: 1149-1156, 1997.
32. Sakaria JN, Tibbetts RS, Busley EC, Kennedy AP, Hill DE and Abraham RT: Inhibition of phosphoinositide 3-kinase related kinases by the radiosentizing agent Wortmannin. Cancer Res 58: 4375-4382, 1998.
33. Wyman MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhausebroeck B, Waterfield MD and Panargotou G: Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 16: 1722-1733, 1996.
34. Rao RV, Ellerby HM and Bredesen DE: Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 11: 372-380, 2004.
35. Breckenridge DG, Germain M, Mathai JP, Nguyen M and Shore GC: Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22: 8608-8618, 2003.